Document:

Exhibit 10.4

 

Execution version

 

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

[*****] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.

 

2019 AMENDMENT

 

TO GLOBAL MASTER SERVICES AGREEMENT AND

 

TO SUPPLY AGREEMENT

 

This Amendment (“2019 Amendment”) to the Global Master Services Agreement dated 1 January 2015 (“MSA”) and the Supply Agreement dated 1 January 2016 (“Supply Agreement”) is entered into as of 2 July, 2018 by and between

 

(1)                                 Shire International GmbH, a Swiss limited liability company having its registered office at Zählerweg 10, 6301 Zug, Switzerland (“Shire International”);

 

(2)                                 Shire Pharmaceuticals Ireland Ltd., an Irish limited liability company having its registered office at Block 2 & 3 Miesian Plaza, 50 – 58 Baggot Street Lower, Dublin 2, Ireland (“SPIL”); and

 

(3)                                 Centogene AG, a German stock corporation incorporated under the laws of the Federal Republic of Germany with principal office in Restock, registered with the district court (‘Amtsgericht’) in Rostock under HRB 13225 and having a business address at Am Strande 7, 18055 Restock, Germany (“Centogene”).

 

PREAMBLE

 

(A)                               Shire International and Centogene have entered into the MSA under which Centogene provides certain diagnostic testing services on the basis of dried-blood-spot (DBS) cards for the purpose of identifying patients suffering from lysosomal storage and other rare diseases to Shire International and its affiliates.

 

(B)                               In addition to the MSA, SPIL and Centogene have entered into the Supply Agreement under which Centogene (i) develops DBS test kits for the use in certain countries as required by SPIL on the basis of Centogene’s existing DBS test kits, (ii) manufactures such DBS test kits and (iii) supplies SPIL and its affiliates with such DBS test kits.

 

(C)                               On 8 March 2016, Shire International and Centogene entered into an amendment of the MSA under which Shire International and Centogene agreed, inter alia, on a flat fee for the performance of diagnostic services for the year 2016 (“2016 Amendment”). In a side letter to the MSA dated 24 November 2016, Shire International and Centogene agreed on certain additional commercial aspects with respect to the year 2016. On 3 May 2017, Shire International, SPIL and Centogene entered into an amendment of the MSA under which Shire International, SPIL and Centogene agreed, inter alia, on a flat fee for the performance of diagnostic services for the years 2017 and 2018 (“2017 Amendment”).

 

 

(D)                               Shire International, SPIL and Centogene now wish to agree on certain financial and other aspects of their cooperation going forward.

 

Now, therefore, Shire International, SPIL and Centogene, intending to be legally bound, hereby agree to amend the MSA and the Supply Agreement as follows:

 

 

DEFINITIONS

 

In this 2019 Amendment any capitalized terms shall have the meaning set forth in the MSA and the Supply Agreement (both as amended from time to time), unless a term is specifically defined under this 2019 Amendment.

 

1.                                      ANNUAL FLAT FEE

 

1.1.                            Annual Flat Fee.  The Parties agree to amend Section 3.6 of the MSA with respect to the calendar year 2019 as follows:

 

Subject to the below, Shire International will make an annual lump sum payment of € [*****] ([*****] Euro) to Centogene for the performance of [*****] of Diagnostic Tests for Morbus Fabry, Morbus Gaucher, Morbus Hunter, MPS1, MPS2, MPS3, MPS4, MPS6 and MPS7 in the calendar year 2019 (“Annual Flat Fee”). The financial terms of the Annual Flat Fee as well as other financial assumptions under the MSA and Supply Agreement are set forth in more detail in Appendix 1 to this 2019 Amendment. Centogene hereby expressly waives any payment claims for Excess Diagnostic Tests under Section 3.6(c) of the MSA; provided, however, that only the first [*****] Diagnostic Tests for MPS1, MPS3, MPS4, MPS6 and MPS7 performed in 2019 will be included in the Annual Flat Fee. Any additional Diagnostic Tests for MPS1, MPS3, MPS4, MPS6 and MPS7 will be invoiced and paid in accordance with Sec. 3.6 (c) of the MSA.

 

1.2.                            Diagnostic Test and Prices.  The Parties agree to replace Exhibit 1 of the MSA (Diagnostic Tests and Prices) in its entirety with a new Exhibit 1 attached to this 2019 Amendment as Appendix 2. Parties acknowledge that the prices reflected therein have been increased as per Section 3.6(g) of the MSA.

 

1.3.                            Reporting.  The payment of the Annual Flat Fee does not relieve Centogene from its obligation under Section 3.4 of the MSA to provide Shire International with detailed monthly summaries of Diagnostic Services actually rendered in the previous month, in the form as attached as Appendix 3 to this 2019 Amendment, including the information on the testing of expired Contract DBS Test Kits as further detailed in the Side Letter between Shire International and Centogene dated 2 July 2018.

 

1.4.                            Upfront Payments.  Centogene will issue at the beginning of each calendar month, a preliminary invoice for a prorated amount of the Annual Flat Fee, i.e. an amount equal to 1/12 of each Annual Flat Fee. Shire International shall make payment within ten (10) Business Days upon receipt of a proper invoice.

 

2.                                      BUSINESS CONTINUITY PLAN

 

Finalization of BCP, the parties hereby attach the latest agreed version of the Business Continuity Plan in Appendix 4.

 

3.                                      OTHER TERMS

 

Other.  All other terms and conditions as set forth in the MSA and the Supply Agreement (as amended from time to time) shall remain in full force and effect.

 

[signature page follows]

 

 

	
Place:
    	
Zug,   Switzerland
    	
 
    	
 
    	
Place:
    	
Berlin
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Date:
    	
2   July 2018
    	
 
    	
 
    	
Date:
    	
06.07.2018
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
for and on behalf of 
    	
 
    	
 
    	
for and on behalf of 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
Shire International GmbH
    	
 
    	
 
    	
Centogene AG
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    
	
/s/ [*****]
    	
 
    	
 
    	
/s/ Richard   Stoffelen
    	
/s/ Frank   Volpers
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Name:
    	
[*****]
    	
 
    	
 
    	
Name:
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title:
    	
Proxy Holder
    	
 
    	
 
    	
Title: 
    	
CFO
    	
VP Legal
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
CENTOGENE   AG
    
	
 
    	
 
    	
 
    	
 
    	
Zimmerstraße   69
    
	
Place:
    	
Dublin, Ireland
    	
 
    	
 
    	
10117   Berlin / Germany
    
	
 
    	
 
    	
 
    	
 
    	
Tel.   +49 (0)30 213000-323
    
	
Date:
    	
2/7/2018
    	
 
    	
 
    	
Tel.   +49 (0)30 213000-328
    
	
 
    	
 
    	
 
    	
 
    	
Email:   office@centogene.com
    
	
 
    	
 
    	
 
    	
Web:   www.centogene.com
    
	
for and on behalf of
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Shire Pharmaceuticals Ireland Ltd.
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
/s/ [*****]
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Name:
    	
[*****]
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Title:
    	
Director
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
Date:
    	
2/7/2018
    	
 
    	
 
    	
 
    	
 
    

 

 

Appendix 1

 

Annual Flat Fee

 

Annual flat fee of € [*****] for 2019, respectively, subject to following assumptions and clarifications as set out below:

 

Notwithstanding the concept of the flat fee, it is hereby clarified that if Centogene performs less than [*****] Diagnostic Tests in 2019, reconciliation will take place in the subsequent calendar year (2020). In the beginning of such subsequent calendar year, Centogene will issue a credit note, against which future Shire International invoices will be offset, for an amount equal to the difference between the annual flat fee and the value of actual tests performed invoiced at the prices set forth in Exhibit 1 of the MSA (Diagnostic Tests and Prices).

 

 

Appendix 2

 

Exhibit 1 (Diagnostic Tests and Prices)

 

The below prices include (where indicated) an additional technology access fee of € [*****] per tested sample.

 

	
Test/procedure
    	
 
    	
Price In € (net)
    	
 
    	
Technology Access Fee in
   € (net)
    
	
Gaucher
    	
 
    	
 
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
[*****] €
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
It a mutation in a family is found there will be an   additional charge
    	
 
    	
 
    	
 
    	
 
    
	
- sample processing
    	
 
    	
[*****] €
    	
 
    	
 
    
	
- per exon
    	
 
    	
[*****] €
    	
 
    	
 
    
	
- in total for homozygous mutation
    	
 
    	
[*****] €
    	
 
    	
 
    
	
- in total for an heterozygous mutation
    	
 
    	
[*****] €
    	
 
    	
 
    
	
For a prenatal analysis there is an additional   charge
    	
 
    	
 
    	
 
    	
 
    
	
- sample processing
    	
 
    	
[*****] €
    	
 
    	
 
    
	
- for contamination control with maternal material
    	
 
    	
[*****] €
    	
 
    	
 
    
	
Fabry
    	
 
    	
 
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
[*****] €
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
If a mutation In a family is found them will be an   additional charge
    	
 
    	
 
    	
 
    	
 
    
	
- sample processing
    	
 
    	
[*****] €
    	
 
    	
 
    
	
- per exon
    	
 
    	
[*****] €
    	
 
    	
 
    
	
For a prenatal analysis there is an additional   charge
    	
 
    	
 
    	
 
    	
 
    
	
- sample processing
    	
 
    	
[*****] €
    	
 
    	
 
    
	
- for contamination control with maternal material
    	
 
    	
[*****] €
    	
 
    	
 
    
	
MPS II (Hunter Disease)
    	
 
    	
 
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
[*****] €
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
MPS Illa (SGSH)
    	
 
    	
 
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
[*****] €
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    

 

 

	
MPS Illb (NAGLU)
    	
 
    	
 
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
[*****] €
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
MPS IIIc (HGSNAT)
    	
 
    	
 
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
MPS IIId (GNS)
    	
 
    	
 
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
[*****] €
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
MLD(SGSH)
    	
 
    	
 
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
MPS I and VI (prices for each)
    	
 
    	
 
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
[*****] €
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
MPS IV
    	
 
    	
 
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
[*****] €
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    
	
MPS VII
    	
 
    	
 
    	
 
    	
 
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
[*****] €
    
	
[*****]
    	
 
    	
[*****] €
    	
 
    	
 
    

 

 

Appendix 3

 

Proforma Monthly Report

 

1.              Monthly diagnostic test report (one line per test performed)

 

[*****]

 

 

Execution version

 

2.              Monthly Expired Contract DBS Test Kit report (one line per country and disease on expired cards received)

 

[*****]

 

 

Appendix 4

 

Business Continuity PlanExhibit 10.5

 

 

LONG-TERM INCENTIVE PLAN

 

CENTOGENE N.V.

 

INTRODUCTION

 

Article 1

 

1.1                              This document sets out the Company’s long-term incentive plan for employees, officers and other service providers who qualify as Eligible Participants.

 

1.2                              The main purposes of this Plan are:

 

a.                                     to attract, retain and motivate Participants with the qualities, skills and experience needed to support and promote the growth and sustainable success of the Company and its business; and

 

b.                                     to incentivise Participants to perform at the highest level and to further the best interests of the Company, its business and its stakeholders.

 

DEFINITIONS AND INTERPRETATION

 

Article 2

 

2.1                              In this Plan the following definitions shall apply:

 

	
Article
    	
 
    	
An   article of this Plan.
    
	
 
    	
 
    	
 
    
	
Award
    	
 
    	
A grant under this Plan in the form of one or more Options, SARs, Shares   of Restricted Stock, RSUs, Other Awards, or a combination of the foregoing.
    
	
 
    	
 
    	
 
    
	
Award Agreement
    	
 
    	
A written agreement between the Company and a   Participant evidencing the grant of an Award to such Participant and   containing such terms as the Committee may determine, consistent with and   subject to the terms of this Plan.
    
	
 
    	
 
    	
 
    
	
Bad Leaver
    	
 
    	
A   Participant who ceases to be an Eligible Participant for Cause.
    
	
 
    	
 
    	
 
    
	
Cause
    	
 
    	
With   respect to a Participant, “cause” as defined in such Participant’s   employment, service or consulting agreement with the Company or a Subsidiary,   or if not so defined (and unless determined otherwise in the applicable Award   Agreement or otherwise by the Committee):

 

a.                                      such Participant’s indictment for any   crime which (i) constitutes a felony, (ii) has, or could
    

 

1

 

	
 
    	
 
    	
reasonably   be expected to have, an adverse impact on the performance of such Participant’s   services to the Company and/or any Subsidiary or (iii) has, or could   reasonably be expected to have, an adverse impact on the business and/or   reputation of the Company and/or any Subsidiary;

 

b.                                      such Participant having been the subject   of any order, judicial or administrative, obtained or issued by any   governmental or regulatory body for any securities laws violation involving   fraud, market manipulation, insider trading and/or unlawful dissemination of   non-public price-sensitive information;

 

c.                                       such Participant’s wilful violation of   the Company’s code of business conduct and ethics, insider trading policy or   other internal policies and regulations established by the Company and/or any   Subsidiary, in each case to the extent applicable to the Participant   concerned;

 

d.                                      gross negligence or wilful misconduct in   the performance of such Participant’s duties for the Company and/or any   Subsidiary or wilful or repeated failure or refusal to perform such duties; e. material breach by such Participant of any employment,   service, consulting or other agreement entered into between such Participant   on the one hand and the Company and/or any Subsidiary on the other;

 

f.                                        conduct by such Participant which should   be considered as an urgent cause within the meaning of Section 7:678   DCC, irrespective of whether that provision applies to such Participant’s   relationship with the Company and/or any Subsidiary; and

 

g.                                      such other acts or omissions to act by   such Participant as reasonably determined by the Committee,

 

provided   that the occurrence of an event described in paragraphs c. through e. above   shall only constitute
    

 

2

 

	
 
    	
 
    	
Cause if   and when such event has not been cured or remedied by the relevant   Participant within thirty days after the Company has provided written notice   to such Participant.
    
	
 
    	
 
    	
 
    
	
Change of Control
    	
 
    	
The   occurrence of any one or more of the following events:

 

a.                                      the direct or indirect change in   ownership or control of the Company effected through one transaction, or a   series of related transactions within a twelve-month period, as a result of   which any Person or group of Persons acting in concert, directly or   indirectly acquires (i) beneficial ownership of more than half of the   Company’s issued share capital and/or (ii) the ability to cast more than   half of the voting rights in the General Meeting;

 

b.                                      at any time during a period of twelve   consecutive months, individuals who at the beginning of such period   constituted the Management Board and the Supervisory Board cease to   constitute a majority of members of the Management Board and the Supervisory   Board, provided that any new member of the Management Board or the   Supervisory Board who was nominated for appointment by the Supervisory Board   by a vote of at least a majority of the Supervisory Directors who either were   Supervisory Directors at the beginning of such twelve-month period or whose   nomination for appointment was so approved, shall be considered as though   such individual were a member of the Management Board or the Supervisory   Board at the beginning of such twelve-month period;

 

c.                                       the consummation of a merger, demerger   or business combination of the Company or any Subsidiary with another Person,   unless such transaction results in the Shares outstanding immediately prior   to the consummation of such transaction continuing to represent (either by   remaining outstanding or by being converted into, or exchanged for, voting   securities of the
    

 

3

 

	
 
    	
 
    	
surviving   or acquiring Person or a parent thereof) at least half of the voting rights   in the General Meeting or in the shareholders’ meeting of such surviving or   acquiring Person or parent outstanding immediately after the consummation of   such transaction; or
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
d.                                      the consummation of any sale, lease,   exchange or other transfer to any Person or group of Persons acting in   concert, not being Subsidiaries, in one transaction or a series of related   transactions within a twelve-month period, of all or substantially all of the   business of the Company and its Subsidiaries.
    
	
 
    	
 
    	
 
    
	
Committee
    	
 
    	
Any of   the following bodies, as applicable:

 

a.                                      the Management Board, to the extent the   administration or operation of this Plan relates to the grant of Awards to   Eligible Participants who are not Managing Directors or Supervisory   Directors, as well as any other matter relating to such Awards;

 

b.                                      the Supervisory Board, to the extent the   administration or operation of this Plan relates to the grant of Awards to   Eligible Participants who are members of the compensation committee   established by the Supervisory Board, as well as any other matter relating to   such Awards; or

 

c.                                       the compensation committee established   by the Supervisory Board for all other matters relating to the administration   or operation of the Plan.
    
	
 
    	
 
    	
 
    
	
Company
    	
 
    	
Centogene   N.V.
    
	
 
    	
 
    	
 
    
	
Consultant
    	
 
    	
Any Person, other than a Managing   Director, Supervisory Director or Employee, who is an adviser or consultant   engaged by the Company and/or a Subsidiary to render bona fide services to   the Company and/or a Subsidiary.
    
	
 
    	
 
    	
 
    
	
DCC
    	
 
    	
The Dutch Civil Code.
    
	
 
    	
 
    	
 
    
	
Eligible Participant
    	
 
    	
Any Managing Director, Supervisory Director,   Employee or Consultant.
    
	
 
    	
 
    	
 
    
	
Employee
    	
 
    	
Any Person, other than a Managing Director or   a Supervisory
    

 

4

 

	
 
    	
 
    	
Director, who is an employee or officer of the   Company and/or a Subsidiary.
    
	
 
    	
 
    	
 
    
	
Exercise Date
    	
 
    	
The date on which an Award is duly exercised   by or on behalf of the Participant concerned.
    
	
 
    	
 
    	
 
    
	
Exercise Price
    	
 
    	
The exercise price applicable to an Award.
    
	
 
    	
 
    	
 
    
	
FMV
    	
 
    	
The closing price of a Share on the relevant date   (or, if there is no reported sale of Shares on such date, on the last   preceding date on which any such reported sale occurred) on the principal   stock exchange where Shares have been admitted for trading, unless determined   otherwise by the Committee.
    
	
 
    	
 
    	
 
    
	
General Meeting
    	
 
    	
The Company’s general meeting of shareholders.
    
	
 
    	
 
    	
 
    
	
Good Leaver
    	
 
    	
A Participant who ceases to be an Eligible   Participant and who is not a Bad Leaver.
    
	
 
    	
 
    	
 
    
	
Grant Date
    	
 
    	
The date on which the Committee decides to   grant an Award, or such later effective date applicable to such Award as may   be determined by the Committee.
    
	
 
    	
 
    	
 
    
	
Management Board
    	
 
    	
The Company’s management board.
    
	
 
    	
 
    	
 
    
	
Managing Director
    	
 
    	
A member of the Management Board.
    
	
 
    	
 
    	
 
    
	
Option
    	
 
    	
The right to subscribe for, or otherwise   acquire, one Plan Share.
    
	
 
    	
 
    	
 
    
	
Other Award
    	
 
    	
An Award which does not take the form of an   Option, SAR, Share of Restricted Stock or RSU, and which may be denominated   or payable in, valued in whole or in part by reference to, or otherwise based   on or related to Shares or factors which may influence the value of Shares,   including cash-settled financial instruments and financial instruments which   are convertible into or exchangeable for Plan Shares.
    
	
 
    	
 
    	
 
    
	
Participant
    	
 
    	
The holder of an Award, including, as the   context may require, the rightful heir(s) of a previous holder of such   Award having acquired such Award as a result of the death of such previous   holder.
    
	
 
    	
 
    	
 
    
	
Performance Criteria
    	
 
    	
The   performance criteria applicable to an Award.
    
	
 
    	
 
    	
 
    
	
Person
    	
 
    	
A natural   person, partnership, company, association, cooperative, mutual insurance   society, foundation or any other entity or body which operates externally as   an
    

 

5

 

	
 
    	
 
    	
independent   unit or organisation.
    
	
 
    	
 
    	
 
    
	
Plan
    	
 
    	
This long-term incentive plan.
    
	
 
    	
 
    	
 
    
	
Plan Share
    	
 
    	
A Share underlying   an Award.
    
	
 
    	
 
    	
 
    
	
Replacement Award
    	
 
    	
An Award granted in assumption of, or in   substitution or exchange for, long-term incentive awards   previously granted by a Person acquired (or whose business   is acquired) by the Company or a Subsidiary or with which the Company or a   Subsidiary merges or forms a business combination, as reasonably determined by the Committee.
    
	
 
    	
 
    	
 
    
	
Restricted Stock
    	
 
    	
Plan Shares subject to such   restrictions as the Committee may impose, including with respect to voting   rights and the right to receive dividends or other distributions made by the   Company.
    
	
 
    	
 
    	
 
    
	
RSU
    	
 
    	
The right to receive, in cash, in assets, in   the form of Plan Shares valued at FMV, or a combination thereof, the FMV of   one Share on the Exercise Date.
    
	
 
    	
 
    	
 
    
	
SAR
    	
 
    	
The right to receive, in cash, in assets, in   the form of Plan Shares valued at FMV, or a combination thereof, the excess   of the FMV of one Share on the applicable Exercise Date over the applicable   Exercise Price.
    
	
 
    	
 
    	
 
    
	
Section 409A IRC
    	
 
    	
Section 409A of the United   States Internal Revenue Code of 1986, as amended, and the   rules, regulations and guidance promulgated pursuant thereto.
    
	
 
    	
 
    	
 
    
	
Share
    	
 
    	
A share in the Company’s capital.
    
	
 
    	
 
    	
 
    
	
Subsidiary
    	
 
    	
A subsidiary of the Company within the meaning   of Section 2:24a DCC.
    
	
 
    	
 
    	
 
    
	
Supervisory Board
    	
 
    	
The Company’s supervisory board.
    
	
 
    	
 
    	
 
    
	
Supervisory Director
    	
 
    	
A member of the Supervisory Board.
    

 

2.2                              References to statutory provisions are to those provisions as they are in force from time to time.

 

2.3                              Terms that are defined in the singular have a corresponding meaning in the plural.

 

2.4                              Words denoting a gender include each other gender.

 

2.5                              Except as otherwise required by law, the terms “written” and “in writing” include the use of electronic means of communication.

 

6

 

ADMINISTRATION

 

Article 3

 

3.1                              This Plan shall be administered by the Committee. The Committee’s powers and authorities under this Plan include the authority to perform the following matters, in each case consistent with and subject to the terms of this Plan:

 

a.                                     designating Persons to whom Awards are granted;

 

b.                                     deciding to grant Awards;

 

c.                                      determining the form(s) and type(s) of Awards being granted and setting the terms and conditions applicable to such Awards, including:

 

i.                                        the number of Plan Shares underlying Awards;

 

ii.                                    whether, to which extent, and under which circumstances Awards may be exercised or settled in cash or assets (including other Awards), or some combination thereof, in lieu of Plan Shares and vice versa, or cancelled, forfeited or suspended;

 

iii.                                whether, to which extent and under which circumstances a Participant may designate another Person owned or controlled by him as recipient or beneficiary of his Awards;

 

iv.                                 whether and to which extent Awards are subject to Performance Criteria and/or restrictive covenants (including non-competition, non-solicitation, confidentiality and/or Share ownership requirements);

 

v.                                     the method(s) by which Awards may be exercised, settled or cancelled;

 

vi.                                 whether, to which extent and under which circumstances, the exercise, settlement or cancellation of Awards may be deferred or suspended;

 

d.                                     amending or waiving the terms applicable to outstanding Awards (including Performance Criteria), subject to the restrictions imposed by Article 9 and provided that no such amendment shall take effect without the consent of the affected Participant(s), if such amendment would materially and adversely affect the rights of the Participant(s) under such Awards, except to the extent that any such amendment is made to cause this Plan or the Awards concerned to comply with applicable law, stock exchange rules, accounting principles or tax rules and regulations;

 

e.                                      correcting any defect, supplying any omission or reconciling any inconsistency in the Plan or any Award Agreement;

 

f.                                       making any determination under, and interpreting the terms of, this Plan, any rules or regulations issued pursuant to this Plan and any Award Agreement;

 

g.                                     settling any dispute between the Company and any Participant (including any beneficiary of his Awards) regarding the administration and operation of this Plan,

 

7

 

any rules or regulations issued pursuant to this Plan, and any Award Agreement entered into with such Participant; and

 

h.                                     making any other determination or taking any other action which the Committee considers to be necessary, useful or desirable in connection with the administration or operation of this Plan.

 

3.2                              The Committee may issue further rules and regulations for the administration and operation of this Plan, consistent with and subject to the terms of this Plan.

 

3.3                              All decisions of the Committee shall be final, conclusive and binding upon the Company and the Participants (including beneficiaries of Awards).

 

AWARDS

 

Article 4

 

4.1                              Awards can only be granted to Eligible Participants, unless the Committee decides otherwise.

 

4.2                              No Award is intended to confer any rights on the relevant Participant except as set forth in the applicable Award Agreement. In particular, no Award should be construed as giving any Participant the right to remain employed by or to continue to provide services for the Company or any Subsidiary.

 

4.3                              Awards shall be granted for no consideration or for such minimal cash consideration as may be required by applicable law.

 

4.4                              Awards may be granted alone or in addition or in tandem with any other Award and/or any award under any other plan of the Company or any Subsidiary. Awards granted in addition or in tandem with any other Award and/or any award under any other plan of the Company or any Subsidiary may be granted simultaneously or at different times.

 

4.5                              Each Award shall be evidenced by an Award Agreement entered into between the Company and the Participant concerned. Until an Award Agreement has been entered into between the Company and the relevant Participant, no rights can be derived from the Awards concerned by such Participant.

 

4.6                              Plan Shares, including Awards in the form of Shares of Restricted Stock, shall be delivered in such form(s) as may be determined by the Committee and shall be subject to such stop transfer orders and other restrictions as the Committee may deem required or advisable. Furthermore, the Committee may determine that certificates for such Shares shall bear an appropriate legend referring to the terms, conditions and restrictions applicable thereto.

 

4.7                              The terms and conditions applicable to Awards, including the time(s) when Awards vest in whole or in part and any applicable Performance Criteria, shall be set by the Committee and may vary between Awards and between Participants, as the Committee deems appropriate. The Committee may also determine whether and under which circumstances

 

8

 

Awards shall be settled automatically upon vesting, without being exercised by the Participant.

 

4.8                              The term of an Award shall be determined by the Committee, but shall not exceed ten years from the applicable Grant Date. Unless determined otherwise by the Committee, if the exercise of an Award is prohibited by applicable law or the Company’s insider trading policy on the last business day of the term of such Award, such term shall be extended for a period of one month following the end of such prohibition.

 

4.9                              Unless determined otherwise by the Committee, Awards cannot be transferred, pledged or otherwise encumbered, except by testament or hereditary law as a result of death of the Participant concerned.

 

4.10                       If, as a result of changes in applicable law, accounting principles or tax rules and regulations, or due to a variation of the composition of the Company’s issued share capital (including a share split, reverse share split, redenomination of the nominal value, or as a result of a dividend or other distribution, reorganization, acquisition, merger, demerger, business combination or other transaction involving the Company or a Subsidiary), an adjustment to this Plan, any Award Agreement and/or outstanding Awards is necessary to prevent dilution or enlargement of the benefits or potential benefits intended to be made available under this Plan, the Committee may adjust equitably any or all of:

 

a.                                     the number of Plan Shares available under this Plan;

 

b.                                     the number of Plan Shares underlying outstanding Awards; and/or

 

c.                                      the Exercise Price or other terms applicable to outstanding Awards.

 

4.11                       Any rights, payments and benefits under any Award shall be subject to repayment and/or recoupment by the Company in accordance with applicable law, stock exchange rules and such policies and procedures as the Company may adopt from time to time.

 

4.12                       The Company may withhold from any outstanding Award, any payment, issuance or transfer to be made under such Award, or any other compensation or amount owed by the Company to the Participant holding such Award, an amount (in cash, in assets, in the form of Shares or other Awards, or a combination thereof) equal to the withholding taxes and other costs due, or to be withheld, by the Company or any Subsidiary in respect of the grant, exercise or settlement of such Award.

 

TYPES OF AWARDS

 

Article 5

 

5.1                              The Committee may grant Awards in the form of Options, SARs, Shares of Restricted Stock, RSUs, Other Awards or a combination of the foregoing.

 

5.2                              Upon the exercise or settlement of vested Options, the Company shall be obliged to deliver to the Participant concerned (or the beneficiary of such Options, as applicable), the Plan

 

9

 

Shares underlying such Options (unless otherwise set forth in the Award Agreement).

 

5.3                              Upon the exercise or settlement of vested SARs, the Company shall be obliged to pay to the Participant concerned (or the beneficiary of such SARs, as applicable) an amount equal to the number of Plan Shares underlying such SARs multiplied by the excess, if any, of the FMV of one Share on the applicable Exercise Date over the applicable Exercise Price. The Company may satisfy such payment obligation in cash, in assets, in the form of Shares valued at FMV, or a combination thereof, at the discretion of the Committee.

 

5.4                              The exercise by a Participant of his rights attached to Shares of Restricted Stock shall be subject to such restrictions as the Committee may impose, including with respect to voting rights and the right to receive dividends or other distributions made by the Company. Upon the vesting of Shares of Restricted Stock, any such restrictions and conditions shall lapse with respect to those Shares. If an Award in the form of Shares of Restricted Stock is cancelled or otherwise terminated, the Participant shall be obliged to transfer all of his unvested Shares of Restricted Stock to the Company promptly and for no consideration.

 

5.5                              Upon the exercise or settlement of vested RSUs, the Company shall be obliged to pay to the Participant concerned (or the beneficiary of such RSUs, as applicable) an amount equal to the number of Plan Shares underlying such RSUs multiplied by the FMV of one Share on the applicable Exercise Date. The Company may satisfy such payment obligation in cash, in assets, in the form of Shares valued at FMV, or a combination thereof, at the discretion of the Committee (unless otherwise set forth in the Award Agreement).

 

5.6                              The Committee may determine that a Participant holding one or more RSUs is entitled to receive dividends and other distributions made by the Company on the Shares, as if such Participant held the Plan Shares underlying such RSUs. The Committee may impose restrictions with respect to such entitlement.

 

PERFORMANCE CRITERIA

 

Article 6

 

6.1                              The Committee may condition the right of a Participant to exercise one or more of his Awards, and the timing thereof, upon the achievement or satisfaction of such Performance Criteria as may be determined by the Committee, within periods specified by the Committee.

 

6.2                              If an Award is subject to Performance Criteria which must be achieved or satisfied within a period specified by the Committee for that purpose, such Award can only be exercised or settled at or after the end of that period.

 

6.3                              Performance Criteria may be measured on an absolute or relative basis and may be established on a Company-wide basis or with respect to one or more business units, divisions, Subsidiaries and/or business segments. Relative performance may be measured against a group of peer companies determined by the Committee, financial market indices and/or 

 

10

 

other objective and quantifiable indices. Performance Criteria may relate to performance by the Company and/or by the Participant concerned.

 

6.4                              If the Committee determines that a change in the business, operations, group structure or capital structure of the Company, or other events or circumstances, render certain Performance Criteria applicable to outstanding Awards unsuitable or inappropriate, the Committee may amend or waive such Performance Criteria, in whole or in part, as the Committee deems appropriate.

 

PLAN SHARES AVAILABLE FOR AWARDS

 

Article 7

 

7.1                              Subject to Articles 4.10 and 7.2, (i) the maximum number of Plan Shares underlying Awards which are not Replacement Awards shall not exceed 13% of the Company’s issued and outstanding share capital Shares as of the date of this Plan provided that, on January 1, 2020 and on January 1 of each calendar year thereafter, such maximum number shall be increased with an additional number of Shares equal to 3% of the Company’s issued share capital on such date (or any lower number of Shares as determined by the Committee).

 

7.2                              Plan Shares underlying Awards, except for Replacement Awards, which expire, which are cancelled or otherwise terminated, or which are exercised or settled in cash or assets in lieu of Plan Shares, shall again be available under this Plan and shall not be counted towards the limit imposed by Article 7.1.

 

VESTING, EXERCISE AND SETTLEMENT

 

Article 8

 

8.1                              Each Award Agreement shall contain the vesting schedule and, where relevant, delivery schedule (which may include deferred delivery later than the vesting dates) for the relevant Awards.

 

8.2                              Only vested Awards may be exercised or settled in accordance with their terms. An Award can only be exercised (to the extent it is not settled automatically) by or on behalf of the Participant holding such Award.

 

8.3                              An Award can only be exercised through the use of an electronic system or platform to be designated by the Committee (if and when such system or platform has been set up by the Company), or otherwise by delivering written notice to the Company in a form approved by the Committee.

 

8.4                              Subject to Article 9.1, the Committee shall determine the Exercise Price, provided that the 

 

11

 

Exercise Price for an Award which can be exercised or settled in the form of Plan Shares shall not be less than the aggregate nominal value of such Plan Shares.

 

8.5                              Upon the exercise of an Award, the applicable Exercise Price must immediately be paid in cash, wire transfer of immediately available funds or by check payable to the order of the Company, provided that the Committee, subject to applicable law, may allow that such Exercise Price is satisfied on a cashless basis as follows:

 

a.                                     by means of an immediate sale of Plan Shares underlying the Award concerned, with sale proceeds equal to the Exercise Price being paid to the Company on behalf of the relevant Participant and any remaining sale proceeds (less applicable costs and taxes, if any) being paid to such Participant;

 

b.                                     as a result of the relevant Participant forfeiting his entitlement to receive part of the Plan Shares underlying the Award concerned at FMV on the Exercise Date and charging the aggregate nominal value of the remaining Plan Shares underlying such Award against the Company’s reserves; and/or

 

c.                                      as a result of the relevant Participant surrendering and transferring Shares to the Company (which may include Plan Shares underlying the Award concerned) at FMV on the Exercise Date.

 

8.6                              The Company is authorized to withhold from any Award granted or any payment due or transfer made under any Award or under the Plan or from any compensation or other amount owing to a Participant the amount (in cash, Shares, other Awards, other property, net settlement or any combination thereof) of applicable withholding taxes due in respect of an Award, its exercise or settlement or any payment or transfer under such Award or under the Plan and to take such other action (including providing for elective payment of such amounts in cash or Shares by the Participant) as may be necessary in the option of the Company to satisfy all obligations for the payment of such taxes

 

8.7                              When an Award is exercised or settled in the form of Plan Shares, the Company shall, at the discretion of the Committee, subject to applicable law and the Company’s insider trading policy:

 

a.                                     issue new Plan Shares to the relevant Participant; or

 

b.                                     transfer existing Plan Shares held by the Company to the relevant Participant,

 

provided, in each case, that Plan Shares may be delivered in the form of book-entry securities representing those Plan Shares (or beneficial ownership of those Plan Shares entitling the holder to exercise or direct the exercise of voting rights attached thereto) credited to the securities account designated by the relevant Participant. Furthermore, Plan Shares may be delivered as described in the previous sentence to a Person designated by the relevant Participant, with the prior approval of the Committee, as beneficiary of his Award.

 

8.8                              If an Award is exercised or settled in the form of Plan Shares and such Award does not relate to a whole number of Plan Shares, the number of Plan Shares underlying such 

 

12

 

Award shall be rounded down to the nearest integer.

 

PRICING RESTRICTIONS FOR OPTIONS AND SARS

 

Article 9

 

9.1                              Except for Replacement Awards, the Exercise Price for an Option or SAR shall not be less than the higher of:

 

a.                                     the FMV of a Plan Share on the applicable Grant Date and, in case of a SAR being granted in connection with an Option, on the Grant Date of such Option; or

 

b.                                     the nominal value of a Plan Share.

 

9.2                              Except as provided in Article 4.10, the Committee may not, without prior approval of the General Meeting, seek to effect any re-pricing of any outstanding “underwater” Option or SAR by:

 

a.                                     amending or modifying the terms of such Award to lower the Exercise Price;

 

b.                                     cancelling such Award and granting in exchange either (i) replacement Options or SARs having a lower Exercise Price, or (ii) Restricted Stock, RSUs or Other Awards; or

 

c.                                      cancelling or repurchasing such Award for cash, assets or other securities.

 

9.3                              Options and SARs will be considered to be “underwater” within the meaning of Article 9.1 at any time when the FMV of the Plan Shares underlying such Awards is less than the applicable Exercise Price.

 

U.S. PARTICIPANTS

 

Article 10

 

10.1                       With respect to any Award subject to Section 409A IRC, this Plan and the applicable Award Agreement are intended to comply with the requirements of Section 409A IRC, the provisions of this Plan and such Award Agreement shall be interpreted in a manner that satisfies the requirements of Section 409A IRC, and this Plan shall be operated accordingly. If any provision of this Plan or any term or condition of any Award subject to Section 409A IRC would otherwise frustrate or conflict with this intent, the provision, term or condition will be interpreted and deemed amended so as to avoid this conflict.

 

10.2                       If all or part of any payments made, or other benefits conferred, under any Award subject to Section 409A IRC constitutes deferred compensation for purposes of Section 409A IRC as a result of a “separation from service” of the relevant Participant (other than due to his death) within the meaning of Section 409A IRC while such Participant is a “specified employee” under Section 409A IRC, then such payment or benefit shall not be made or conferred until six months and one business day have elapsed after the date of such 

 

13

 

“separation from service”, except as permitted under Section 409A IRC.

 

10.3                       If an Award subject to Section 409A IRC includes a “series of installment payments” within the meaning of Section 1.409A-2(b)(2)(iii) of the United States Treasury Regulations, the right of the relevant Participant to such series of installment payments shall be treated as a right to a series of separate payments and not as a right to a single payment, and if such an Award includes “dividend equivalents” within the meaning of Section 1.409A-3(e) of the United States Treasury Regulations, the right of the relevant Participant to such dividend equivalents shall be treated separately from the right to other amounts or other benefits under such Award.

 

10.4                       For any Award subject to Section 409A IRC that provides for accelerated distribution on a Change of Control of amounts that constitute “deferred compensation” as defined in Section 409A IRC, if the event that constitutes such Change of Control does not also constitute a change in the ownership or effective control of the Company, or in the ownership of a substantial portion of the Company’s assets (in either case, as defined in Section 409A IRC), such amount shall not be distributed on such Change in Control but instead shall vest as of the date of such Change of Control and shall be paid on the scheduled payment date specified in the applicable Award Agreement, except to the extent that earlier distribution would not result in the relevant Participant incurring any additional tax, penalty, interest or other expense under Section 409A IRC.

 

10.5                       Notwithstanding the foregoing in this Article 10, the tax treatment of the benefits provided under this Plan or any Award Agreement is not warranted or guaranteed, and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by a U.S. Participant on account of non-compliance with Section 409A IRC.

 

LEAVER

 

Article 11

 

11.1                       If a Participant becomes a Good Leaver, unless otherwise determined by the Committee or set forth in an Award Agreement:

 

a.                                     all vested Awards that have not yet been exercised or settled must be exercised or settled in accordance with their terms within a period specified by the Committee and, if such Awards are not exercised or (through no fault of the Participant concerned) not settled within such period, they shall be cancelled automatically without compensation for the loss of such Awards; and

 

b.                                     all unvested Awards of such Participant shall be cancelled automatically without compensation for the loss of the such Awards, unless the Committee decides otherwise.

 

11.2                       If a Participant becomes a Bad Leaver, all vested Awards of such Participant which have 

 

14

 

not been exercised or settled, as well as all unvested Awards of such Participant, shall be cancelled automatically without compensation for the loss of such Awards.

 

CHANGE OF CONTROL

 

Article 12

 

12.1                       If long-term incentive awards are granted in assumption of, or in substitution or exchange for, outstanding Awards in connection with a Change of Control and the Committee has determined that such awards are sufficiently equivalent to the outstanding Awards concerned, then such outstanding Awards shall be cancelled and terminated upon the replacement awards being granted to the Participants concerned.

 

12.2                       If, in connection with a Change of Control, outstanding Awards are not replaced by long-term incentive awards as described in Article 12.1, or are replaced by long-term incentive awards which the Committee does not consider to be sufficiently equivalent to such outstanding Awards, then such Awards shall immediately vest and, where relevant, settle in full, unless the Committee decides otherwise.

 

12.3                       For purposes of this Article 12, awards shall not be considered to be “sufficiently equivalent” to outstanding Awards, if the underlying securities are not widely held and publicly traded on a regulated national stock exchange.

 

LOCK-UP

 

Article 13

 

In connection with any registration of the Company’s securities, to the extent requested by the Company or the underwriters managing any public offering of the Company’s securities, and except (a) as otherwise approved by the Committee, or (b) pursuant to any exceptions approved by the underwriters, Shares acquired by a Participant pursuant to the issuance, vesting, exercise, or settlement of any Award granted hereunder may not be sold, transferred, or otherwise disposed of prior to such period following the effective date of such registration as designated by the underwriters, not to exceed 180 days following such registration (the “Lock-Up Period”). The Company may impose stop-transfer instructions with respect to the Shares subject to the foregoing restriction until the end of such Lock-Up Period.

 

DATA PROTECTION

 

Article 14

 

14.1                       The Company may process personal data relating to the Participants in connection with the administration and operation of this Plan. The personal data of the Participants which may be processed in this respect may include a copy of an identification document, contact details and bank and securities account numbers. Each Participant’s personal data shall 

 

15

 

be stored by the Company for such time period as is necessary to administer such Participant’s participation in the Plan or as otherwise permitted under applicable law.

 

14.2                       Each Participant’s personal data shall be handled by the Company in a proper and careful manner in accordance with applicable law, including the General Data Protection Regulation (GDPR) and the rules and regulations promulgated pursuant thereto. Participants have the right to lodge complaints with an applicable supervisory authority regarding the Company’s processing of personal data pursuant to this Plan.

 

14.3                       The Company shall implement technical and organisational measures designed to protect personal data processed pursuant to Article 13.1. Personnel or third parties that have access to such personal data shall be bound by confidentiality obligations.

 

14.4                       The Company shall abide by any statutory rights the Participants may have regarding their respective personal data processed pursuant to Article 13.1, which includes the right to access, rectification, erasure, restriction of processing, objection to processing and portability of such personal data.

 

14.5                       In connection with the administration and operation of this Plan, the Company may transfer personal data processed pursuant to Article 13.1 to one or more third parties, provided that there is a legitimate interest in doing so. Where such third parties are located outside the European Economic Area in countries that are not considered to provide for an adequate level of data protection, the Company shall ensure that sufficient data protection safeguards are put in place, failing which explicit consent for such transfer shall be obtained from the Participant(s) concerned.

 

14.7                       The Company may establish one or more privacy policies providing further information on data protection and applying to the processing of personal data of the Participants by the Company in connection with the administration and operation of this Plan.

 

AMENDMENT AND TERMINATION

 

Article 15

 

Pursuant to a resolution to that effect, the Supervisory Board may amend, supplement or terminate this Plan, provided that no such amendment, supplement or termination shall take effect without:

 

a.                                     approval of the General Meeting, if such approval is required by applicable law or stock exchange rules; and/or

 

b.                                     the consent of the affected Participant(s), if such action would materially and adversely affect the rights of such Participant(s) under any outstanding Award, except to the extent that any such amendment, supplement or termination is made to cause this Plan to comply with applicable law, stock exchange rules, accounting principles or tax rules and regulations.

 

16

 

GOVERNING LAW AND JURISDICTION

 

Article 16

 

This Plan shall be governed by and shall be construed in accordance with the laws of the Netherlands. Subject to Article 3.1 paragraph g., any dispute arising in connection with these rules shall be submitted to the exclusive jurisdiction of the competent court in Amsterdam, the Netherlands.

 

17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00300-of-00352.parquet"}]]